Avelas Biosciences is a biotechnology company focused on developing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a pivotal trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.
Aug 04, 2020
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer SurgeryRead more
May 19, 2020
Avelas and AxelaRx Announce Collaboration to Accelerate the Development of Promising Nerve Imaging AgentsRead more
Feb 26, 2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020Read more